Comparison of 3 investigational assays for the free form of prostate specific antigen

被引:40
作者
Nixon, RG [1 ]
Meyer, GE
Blase, AB
Gold, MH
Brawer, MK
机构
[1] Univ Washington, Sch Med, Urol Sect, Seattle Puget Sound Vet Adm Med Ctr, Seattle, WA 98108 USA
[2] Univ Washington, Med Ctr, Dept Urol, Seattle, WA 98195 USA
[3] Hybritech Inc, San Diego, CA USA
关键词
prostatic neoplasms; prostate-specific antigen; biological markers;
D O I
10.1016/S0022-5347(01)62913-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Measuring percent free/total prostate specific antigen (PSA) versus total PSA alone has been shown to enhance the stratification of cases with and without prostate cancer. We compared the diagnostic performance of 3 free PSA assays when values were interchanged over a common total PSA denominator. Materials and Methods: Archival sera from 123 consecutively accrued patients (25 with prostate cancer, 98 with no evidence of malignancy) who had pre-biopsy total PSA levels from 2.0 to 20.0 ng./ml, were obtained from our specimen bank. Serum specimens were analyzed using the Hybritech Tandem R,dagger Dianon Systems double dagger and Chiron ACS 180 free PSA assays. Total PSA was measured using the Hybritech Tandem R total PSA assay. Linear regression was performed to evaluate the correlation and agreement among assays. Sensitivity and specificity of cancer detection were calculated to compare diagnostic performance. Results: The required percent free PSA cutoffs were different among the 3 free PSA assays. The cutoffs to ensure a 95% sensitivity of cancer detection were 22, 34 and 34%, and the number of negative biopsies that were prevented at these cutoffs (specificity) was 38, 19 and 33% for the Hybritech, Dianon, and Chiron assays, respectively. Conclusions: The results among the different assays were not interchangeable, Clinicians should be aware that different percent free PSA cutoffs need to be used based on the type of free and total PSA assays, and that not all assays diagnostically perform the same.
引用
收藏
页码:420 / 425
页数:6
相关论文
共 21 条
  • [1] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
    BLAND, JM
    ALTMAN, DG
    [J]. LANCET, 1986, 1 (8476) : 307 - 310
  • [2] Brawer M. K., 1995, Journal of Urology, V153, p464A
  • [3] PSA IN THE SCREENING, STAGING AND FOLLOW-UP OF EARLY-STAGE PROSTATE-CANCER - A REVIEW OF RECENT DEVELOPMENTS
    BRAWER, MK
    LANGE, PH
    [J]. WORLD JOURNAL OF UROLOGY, 1989, 7 (01) : 7 - 11
  • [4] SCREENING FOR PROSTATIC-CARCINOMA WITH PROSTATE SPECIFIC ANTIGEN
    BRAWER, MK
    CHETNER, MP
    BEATIE, J
    BUCHNER, DM
    VESSELLA, RL
    LANGE, PH
    [J]. JOURNAL OF UROLOGY, 1992, 147 (03) : 841 - 845
  • [5] ASSAY VARIABILITY IN SERUM PROSTATE-SPECIFIC ANTIGEN DETERMINATION
    BRAWER, MK
    DAUM, P
    PETTEWAY, JC
    WENER, MH
    [J]. PROSTATE, 1995, 27 (01) : 1 - 6
  • [6] Brawer MK, 1997, PROSTATE, V30, P269
  • [7] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    DODDS, KM
    COPLEN, DE
    YUAN, JJJ
    PETROS, JA
    ANDRIOLE, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) : 1156 - 1161
  • [8] DETECTION OF ORGAN-CONFINED PROSTATE-CANCER IS INCREASED THROUGH PROSTATE-SPECIFIC ANTIGEN-BASED SCREENING
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    BASLER, JW
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (08): : 948 - 954
  • [9] CATALONA WJ, 1995, JAMA-J AM MED ASSOC, V274, P1214
  • [10] CATALONA WJ, 1997, J UROL 2, V157, P11